Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 25, 2021Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial
-
Oct 22, 2021Pivotal trial met primary and all key secondary endpoints
-
Oct 20, 2021Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
-
Aug 30, 2021Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks
-
Aug 6, 2021Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile
-
Jun 28, 2021* Study also shows more people on Soliqua 100/33 had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin
-
Jun 28, 2021- Respiratory syncytial virus (RSV) is the leading cause of hospitalization in all infants1,2
-
Jun 17, 2021* $425 million investment in Sanofi's Swiftwater, PA facility expands production of Fluzone® High-Dose Quadrivalent for people 65 and older in the U.S.
-
Jun 1, 2021* This combination vaccine may simplify execution and reduce shots needed to complete CDC's recommended child and adolescent immunization schedule
-
May 17, 2021- Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patients
-
Apr 26, 2021Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.1-5
-
Oct 21, 2020* $1 million in research funding to support PD GENEration, a first-of-its-kind national study offering free genetic testing and counseling for people with Parkinson's disease (PD)
-
Oct 13, 2020Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option
-
Sep 14, 2020* Designation based on positive results from Part A of pivotal Phase 3 trial
-
Sep 9, 2020- New data on investigational brain-penetrant BTK inhibitor tolebrutinib (SAR442168) further support its potential in modulating disabling inflammatory processes within the central nervous system
-
Aug 17, 2020* Further strengthens core R&D areas of autoimmune and allergic diseases
-
Jul 31, 2020- Promising vaccine candidate selected by U.S. government’s Operation Warp Speed
-
Jul 30, 2020- Nirsevimab reduced respiratory syncytial virus (RSV) lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent1
-
Jul 14, 2020* New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines
-
Jun 19, 2020* Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent
-
Jun 15, 2020- Preclinical data show anti-tumor activity in Sanofi's investigational compounds, including an oral selective estrogen receptor degrader (SERD) and an anti-CEACAM5 antibody-drug conjugate
-
Jun 14, 2020* Additional donation of factor therapy fulfills 2014 pledge to donate up to an unprecedented 1 billion IUs for humanitarian use
-
Jun 2, 2020Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone
-
May 29, 2020Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up, CRs are 20% representing a 200% increase over two years
-
May 26, 2020- In the pivotal trial, more than twice as many children achieved clear or almost clear skin and more than four times achieved itch reduction with Dupixent plus topical corticosteroids (TCS) compared to TCS alone
-
May 14, 2020Sutimlimab targets C1-activated hemolysis in cold agglutinin disease (CAD)
-
May 13, 2020- Emerging data demonstrate commitment to advancing cancer care, including two fully in-house investigational compounds: a potential best-in-class oral SERD for breast cancer and a first-in-class anti-CEACAM5 antibody-drug conjugate for non-small cell lung cancer
-
May 12, 2020- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee
-
May 5, 2020Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)
-
Apr 27, 2020- Libtayo decreased the risk of death by 32.4% compared to chemotherapy
-
Apr 27, 2020• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group
-
Apr 24, 2020Latest innovation in quadrivalent meningococcal vaccination designed for use in persons 2 years of age and older in the U.S.
-
Apr 3, 2020- Detailed data to be presented at the Revolutionizing Atopic Dermatitis Conference show adding Dupixent to topical corticosteroids improved skin clearance; average overall disease improved by approximately 80%
-
Mar 16, 2020* U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately
-
Mar 2, 2020* Sarclisa in combination with pomalidomide and dexamethasone (pom-dex) significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial
-
Feb 18, 2020- Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi's well-established recombinant technology platform to expedite a potential COVID-19 vaccine
-
Jan 30, 2020- Acid sphingomyelinase deficiency (ASMD) is a rare, progressive and potentially life-threatening disease for which no treatments are approved
-
Jan 28, 2020If approved, Dupixent would be the first biologic medicine available in the U.S. for these children
-
Jan 23, 2020* Synthorx, Inc. is now a fully owned subsidiary of Sanofi
-
Dec 9, 2019- U.S.-based, state of the art facilities to be established for sustainable production of adjuvanted recombinant vaccine for use in the event of a pandemic
-
Nov 21, 2019- Sutimlimab, an investigational targeted C1s inhibitor, met its primary efficacy endpoint in Phase 3 trial for patients with cold agglutinin disease (CAD)
-
Nov 6, 2019*Oncology: New data from investigational isatuximab pivotal study for the treatment of relapsed/refractory multiple myeloma
-
Nov 4, 2019* Will be available in fall 2020, in time for the 2020-2021 flu season
-
Oct 9, 2019Add-on payment to provide additional Medicare reimbursement for Medicare patients prescribed Cablivi in eligible hospital inpatient settings
-
Sep 30, 2019- CARD is a treatment sequencing trial investigating the efficacy and safety of Jevtana versus abiraterone or enzalutamide after disease progression following initial androgen receptor-targeted agent therapy and docetaxel